Green Thumb Industries Inc. (GTBIF): Results of Operations and Financial Condition
Green Thumb Industries Inc. (GTBIF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gtbif-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Green Thumb Industries Reports Second Quarter 2026 Results CHICAGO and VANCOUVER, British Columbia, August 4, 2026 (GLOBE NEWSWIRE) – Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a
How this was made
The 30-second read
Why it matters
Traders can update models for revenue growth, margin drivers (price compression, RYTHM licensing fees), cash generation, and capital allocation via share repurchases. The DOJ Schedule III reclassification is a notable tax regime change affecting reported tax expense.
Market read
Q2 numbers plus the quantified buyback and tax-regime change provide actionable updates for valuation and near-term sentiment, even without explicit forward guidance in the excerpt.
What to watch
The filing attributes lower income tax expense to DOJ’s April 28, 2026 effective date; investors may need to separate one-time tax relief from sustainable operating improvement.
Background
The filing is Green Thumb’s SEC Form 8-K (Item 2.02) attaching Exhibit 99.1 with Q2 2026 financial results and liquidity updates.
Ticker impact
Green Thumb reported Q2 2026 results: revenue $306.7M (+4.6% YoY), GAAP net income $4.9M, and repurchased about 7.9M shares for $48.3M.
Near-term trading bias likely depends on how investors weigh normalized EBITDA strength versus gross margin decline and higher SG&A.
This is a primary earnings-style disclosure with multiple quantified datapoints (revenue, margins, normalized EBITDA, cash flow, and buyback). However, the excerpt does not include forward guidance, limiting conviction on direction.
Market effects
Cannabis operators may see read-through from DOJ Schedule III reclassification effects on 280E and from ongoing pricing pressure and competition.
Virginia adult-use authorization timeline and new dispensary openings in NJ and PA are incremental catalysts for retail expansion narratives.
Limited direct global relevance; primarily US regulatory and retail rollout dynamics.
Counterpoint
Normalized EBITDA rose, but gross margin fell due to licensing fees and price compression, suggesting underlying pricing power may be deteriorating despite headline growth.
Key entities
- issuerGreen Thumb Industries Inc.
OTCQX-listed cannabis consumer packaged goods company reporting Q2 2026 results and buyback activity.
- counterpartyRYTHM, Inc.
Licensing fees and prior-year IP/hemp sale to RYTHM are cited as drivers of current-period gross margin and other expense.
- regulatorU.S. Department of Justice
Final order effective April 28, 2026 reclassifying state legal medical cannabis to Schedule III, ending 280E for portions of the business.